Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. - Wikidata - awgldk - TriplyDB

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

http://www.wikidata.org/entity/Q33552220

about

Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder The ubiquitin proteasome system in neuropathology A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair Wnt your brain be inflamed? Yes, it Wnt!Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein Alpha-synuclein and tau: teammates in neurodegeneration?A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein.Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.Pentazocine Protects SN4741 Cells Against MPP+-Induced Cell Damage via Up-Regulation of the Canonical Wnt/β-Catenin Signaling Pathway.Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy.Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia Motor and cognitive deficits in aged tau knockout mice in two background strains.Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease.Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.GSK-3 in Neurodegenerative Diseases.Bridging molecular genetics and biomarkers in lewy body and related disorders CSF biomarkers and clinical progression of Parkinson disease.Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cells Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease.Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders What we can learn from animal models about cerebral multi-morbidity.Advances in tau-based drug discovery.

P2860

Q24292861-0B5ACBD0-84A5-4B50-8CE4-A1AB2948A79F Q24304959-AA746EDC-B627-4490-A45D-195650A6A5E3 Q24311461-B1C29CCD-DAFC-4130-AA01-BB6C82B5BEF4 Q24626017-202325B7-9E7C-4F73-8625-5E5B4114FA03 Q24644208-DF169BFA-5062-46A8-8491-F9DC6606BD18 Q26741164-FD72FE90-5100-4F63-B69A-1F0F5EEEA613 Q26744782-6C8F6B91-F862-41A2-8DFA-4B18C22045D4 Q26865502-9D6D0DBB-B0FA-4627-819D-840D7EE583BE Q27022507-2AA7A3AF-8C77-462B-8233-0824388CD9A1 Q27330366-313ADEA3-16F0-4683-AEA4-17E9AC118EAD Q27331743-8F6D947C-1C6D-4B50-B520-223FF2BEF937 Q28250508-891D42B7-F3FA-41F5-9393-619DAA5B125D Q28589470-EDFC9B25-8A9E-4624-A0ED-4C7810F0CE2E Q30541822-2A7234FC-E4A6-4AC6-9DEC-9E083FC548C5 Q30577687-FEFB542E-4A2F-4DD8-A03C-5D5A34F5D9B6 Q33658107-556B059E-369E-4FCC-81E1-EA70DFA34946 Q33666297-80CEA2F9-BBAC-4D0B-88E0-ECA11FCA8AE1 Q33727623-5D05A90B-917E-4DD4-AEBF-57C956F1A8BC Q33770294-F6597656-11B3-4EAF-AFC7-A688AD575559 Q33771694-B3E44B27-BF1D-4136-A01B-8A6B56AB833E Q33794494-D0102A0B-880B-4CE1-B038-10E5E1E7BB42 Q33980640-A37EE359-535F-4ABC-88D8-6FA558F638C1 Q34062509-8F6BABDF-2818-4DD4-AE6B-775A0DCAE10D Q34069284-2EAEF7B6-7688-4024-829F-D3CDEB8AE466 Q34077327-BEE1697D-C765-4726-9D7D-6AA8397DA15D Q34146349-1C46E16D-BA51-44EB-A228-B551F36A14BC Q34292532-3BD329B2-5A22-480A-BC3D-0CDD880BB2CC Q34481921-B7B0D44F-5EEE-49C4-872F-093C2E757674 Q34591096-EDA45629-33E9-4730-928D-DDA7A59FB25B Q34704153-4136D57D-28AB-4DD1-B26F-DB8A57AECAB8 Q34917354-01DA6ED8-1D51-4F0F-8E8A-32191146ADF3 Q35000764-FB58D324-6DE4-48D9-8B0C-2F572DB40C33 Q35001040-F633C848-17C7-43E3-B8B2-7C48B5B0F297 Q35094391-F210D0A9-BB80-457A-9DFC-EA433F680299 Q35106542-D1B8BB1D-635C-4D09-B0B3-C94F1C6A0492 Q35144986-D6F6AB3D-9DFD-4024-8E0A-1AB2C5983FEA Q35164339-DCA3385C-45C0-4481-B476-C1B810A65D6E Q35197096-6C52FC6D-91AA-4511-9551-DD19AA63DDE7 Q35215656-B01F7C92-A7FC-45E6-B0F7-95BB96B3DC1C Q35321539-303D61AE-D537-4574-9894-FDBE598F7257

P2860

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

http://www.wikidata.org/entity/Q33552220

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@ast

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@en

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@nl

type

label

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@ast

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@en

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@nl

altLabel

α-Synuclein contributes to GSK ...... in Parkinson’s disease models

@en

prefLabel

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@ast

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@en

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@nl

P1433

Q33552220-650D91F9-42AE-4FDF-86D7-77A6BC8947B2

P1476

Q33552220-478A79A1-2912-4676-B3ED-22ADF4982F2D

P2093

Q33552220-494E77DF-D34D-42AA-A611-03A5F2C06C22

Q33552220-D2DA1D1A-48BF-48E6-95C3-8E27E335426A

Q33552220-D524AED1-8874-45F7-AB18-1690A9B04460

Q33552220-E1D738A0-0A7F-483F-915B-0D21DBABA10B

P2860

Q33552220-00748FBD-0317-462D-A874-0D2AD4F33BAB

Q33552220-0F9467C4-3D6E-48DF-86A2-B84EB72436C0

Q33552220-10B42935-7D29-4046-A323-8A22F56DEB9F

Q33552220-1372A524-1D12-49DA-BFF5-73380A34C1DE

Q33552220-17F6839A-F6AA-46D3-A278-02D5D3072A84

Q33552220-1E28D487-C786-467F-A5CD-69A59CC1BAEE

Q33552220-216B2E76-F033-4431-8C79-CD046121BBC0

Q33552220-22E0C3D5-013F-4BAB-A281-B2D37FD68097

Q33552220-231B1CFC-D574-47B7-8393-1310D14FFF50

Q33552220-2900D30D-03E6-4CE7-96D2-8293560FA81A

P304

Q33552220-2E0B058B-1745-49C7-A8B6-30AA27B7A504

P31

Q33552220-FB50AFC1-07B6-4FB0-876B-5598C9523820

P356

Q33552220-7C0552B7-3114-40F6-9D52-37CF816E56DD

P407

Q33552220-44B29C9D-3253-4645-9CA8-43A824979534

P433

Q33552220-7E9256F9-B431-48BB-9106-4BA01F224CE2

P478

Q33552220-7BFE6FD3-75EF-4089-ABEE-D66B3C3041DA

P577

Q33552220-750129D6-7C8A-4693-A961-6D3E299B027F

P5875

Q33552220-45EAE1EE-0CD4-4B5D-98A1-09D94B6E4AD5

P698

Q33552220-340C643B-DD23-47B0-87FF-01B70FDA6C9E

P921

Q33552220-37E7BFC8-95FD-4089-BD16-6DB211FD4032

Q33552220-AD75895A-FC66-4C6D-8107-99796029F0EB

Q33552220-CA3C7762-A4FB-4410-A89F-02B9B8924BF0

P932

Q33552220-AC3A528C-18D2-435F-BA98-C84BEF9E46A8

P356

P1433

P1476

Alpha-Synuclein contributes to ...... in Parkinson's disease models.

@en

P2093

Anita Sidhu

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Joyce

http://www.w3.org/2001/XMLSchema#string

Tetyana Duka

http://www.w3.org/2001/XMLSchema#string

Valeriy Duka

http://www.w3.org/2001/XMLSchema#string

P2860

Lewy Body Pathology in Alzheimer's Disease

Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress

alpha-Synuclein locus triplication causes Parkinson's disease

GSK3B polymorphisms alter transcription and splicing in Parkinson's disease

alpha-Synuclein shares physical and functional homology with 14-3-3 proteins

Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

The renaissance of GSK3

Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.

P304

2820-2830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.08-120410

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24280446

http://www.w3.org/2001/XMLSchema#string

P698

19369384

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

phosphorylation

P932

2796901

http://www.w3.org/2001/XMLSchema#string